HC Wainwright Reaffirms Buy Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

HC Wainwright reissued their buy rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a report released on Wednesday morning,Benzinga reports. They currently have a $11.00 price objective on the stock.

Corvus Pharmaceuticals Trading Down 14.8 %

Shares of CRVS stock opened at $3.35 on Wednesday. Corvus Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $10.00. The company’s fifty day moving average price is $4.67 and its 200-day moving average price is $6.08. The stock has a market cap of $215.26 million, a PE ratio of -3.60 and a beta of 0.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06). On average, sell-side analysts forecast that Corvus Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC bought a new stake in Corvus Pharmaceuticals in the 4th quarter worth approximately $47,000. Nwam LLC purchased a new position in Corvus Pharmaceuticals in the 3rd quarter worth about $53,000. PKS Advisory Services LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth approximately $56,000. Alpine Global Management LLC purchased a new position in shares of Corvus Pharmaceuticals during the fourth quarter valued at $62,000. Finally, ExodusPoint Capital Management LP purchased a new position in Corvus Pharmaceuticals during the 4th quarter valued at about $72,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.